Aktiesnakken — Februar 2010
-
Genmab starts HuMax-EGFr combination study
Genmab A/S has announced it has initiated a Phase II study of HuMax-EGFr (zalutumumab) in combination with chemo-radiation to treat non small cell lung cancer (NSCLC).
News-Medical (www.news-medical.net)
-
du kan godt lide det med antal patienter ikke
-
det var jo for at vise at de også kører egfr i de helt store indikationer....172.000
-
ja
-
folk forstår jo ikke at genmab er mega bigtime super liga
-
hvis de lykkes bliver de gigantisk store
-
og andre ville dræbe for bare at have EGFR
-
nej den blev da genoptaget
-
eller?
-
på genmabs side står kun head and neck forsøgene
-
faldt de i portfolio review?
-
nu har jeg rettet min fejl
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind